DOCSLIB.ORG

Caresource Just4me™ Authorization Requirements for Medications Under the Medical Benefit the Provided List Is Not All-Inclusive

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Caresource Just4me™ Authorization Requirements for Medications Under the Medical Benefit the Provided List Is Not All-Inclusive CareSource Just4Me™ Authorization Requirements for Medications Under the Medical Benefit The provided list is not all-inclusive. Any and all medications may be subject to review. This list will be updated quarterly. Revision/Review Date: 1/1/2016 Effective Date: 02/1/2016 Procedure Code Description Brand Authorization Requirements Interferon beta-1a, 30 mcg Avonex, Rebif Not Covered Under Medical Benefit, Pharmacy Only Authorization required for all J1826 providers Rho D immune globulin, human, minidose, 50 mcg (250 i.u.) Hyperho S/D, Micrhogam,Rhogam No authorization required for home, outpatient and MD office J2788 Rho D immune globulin, human, full dose, 300 mcg (1500 i.u.) Hyperho S/D, Gamulin, Rhophylac, No authorization required for home, outpatient and MD office J2790 Rhogam, Bayrho-D Rho D immune globulin, intravenous, human, solvent detergent, 100 Winrho SDF No authorization required for home, outpatient and MD office J2792 IU J9301 Obinutuzumab, 10 mg Injection Gazyva Authorization required for all providers J7508 Tacrolimus Oral Per 5 Mg Astagraf XL Not Covered Under Medical Benefit, Pharmacy Only J1071 Testosterone cypionate, 1 mg Injection Depo-Testosterone Authorization required for all providers J3121 Testosterone enanthate, 1 mg Injection Delatestryl Authorization required for all providers J3145 Testosterone undecanoate, 1 mg Injection Aveed Authorization required for all providers J1930 Lanreotide, 1 mg Somatuline Authorization required for all providers J2353 Octreotide, depot form for intramuscular 1 mg Sandostatin Authorization required for all providers Octreotide, nondepot form for subcutaneous or intravenous 25 mcg Sandostatin Authorization required for all providers J2354 J0171 Adrenalin, epinephrine, 0.1 mg Injection Adrenalin No authorization required for home, outpatient and MD office J1265 Dopamine HCl, 40 mg Intropin No authorization required for home, outpatient and MD office J2315 Naltrexone, depot form, 1 mg Vivitrol Authorization required for all providers J9340 Thiotepa, 15 mg Thioplex No authorization required for home, outpatient and MD office J0636 Calcitriol, 0.1 mcg Injection Calcitrol No authorization required for home, outpatient and MD office J3350 Urea, up to 40 g Injection Urea No authorization required for home, outpatient and MD office Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 g Metvixia No authorization required for home, outpatient and MD office J7309 Alpha 1-proteinase inhibitor (human), not otherwise specified, 10 Zemaira, Prolastin, or Aralast Authorization required for all providers J0256 mg Injection Alpha 1 proteinase inhibitor (human), (GLASSIA), 10 mg Injection Glassia Authorization required for all providers J0257 J0881 Darbepoetin alfa, 1 mcg (non-ESRD use) Aranesp Authorization required for all providers J0882 Darbepoetin alfa, 1 mcg (for ESRD on dialysis) Aranesp Authorization required for all providers J0885 Epoetin alfa, (for non-ESRD use), 1000 units Epogen, Procrit Authorization required for all providers J0886 Epoetin alfa, 1000 units (for ESRD on dialysis) Epogen, Procrit Authorization required for all providers J0670 Mepivacaine HCl, per 10 ml Polocaine No authorization required for home, outpatient and MD office J2001 Lidocaine HCl for intravenous infusion, 10 mg Xylocaine No authorization required for home, outpatient and MD office J2250 Midazolam HCl, per 1 mg Versed No authorization required for home, outpatient and MD office J2704 Propofol, 10 mg Injection Diprivan No authorization required for home, outpatient and MD office J2793 Rilonacept, 1 mg Arcalyst Authorization required for all providers J2795 Ropivacaine HCl, 1 mg Naropin No authorization required for home, outpatient and MD office J2400 Chloroprocaine HCl, per 30 ml Nesacaine No authorization required for home, outpatient and MD office J1742 Ibutilide fumarate, 1 mg Corvert No authorization required for home, outpatient and MD office J2690 Procainamide HCl, up to 1 g Pronestyl No authorization required for home, outpatient and MD office J0745 Codeine phosphate, per 30 mg Codeine Phosphate No authorization required for home, outpatient and MD office J1600 Gold sodium thiomalate, up to 50 mg Mycochrysine, Aurolate No authorization required for home, outpatient and MD office J2910 Aurothioglucose, up to 50 mg Injection Solganal No authorization required for home, outpatient and MD office J0200 Alatrofloxacin mesylate, 100 mg Injection Trovan No authorization required for home, outpatient and MD office J0278 Amikacin sulfate, 100 mg Injection Amikin No authorization required for home, outpatient and MD office J0720 Chloramphenicol sodium succinate, up to 1 g Chloromycetin No authorization required for home, outpatient and MD office J0743 Cilastatin sodium; imipenem, per 250 mg Primaxin No authorization required for home, outpatient and MD office J0744 Ciprofloxacin for intravenous infusion, 200 mg Cipro No authorization required for home, outpatient and MD office J0770 Colistimethate sodium, up to 150 mg Coly-mycin M No authorization required for home, outpatient and MD office J0878 Daptomycin, 1 mg Cubicin No authorization required for home, outpatient and MD office J1267 Doripenem, 10 mg Doribax No authorization required for home, outpatient and MD office J1335 Ertapenem sodium, 500 mg Invanz No authorization required for home, outpatient and MD office J1840 Kanamycin sulfate, up to 500 mg Kantrex No authorization required for home, outpatient and MD office J1850 Kanamycin sulfate, up to 75 mg Kantrex No authorization required for home, outpatient and MD office J2010 Lincomycin HCl, up to 300 mg Lincocin No authorization required for home, outpatient and MD office J2020 Linezolid, 200 mg Zyvox No authorization required for home, outpatient and MD office J2185 Meropenem, 100 mg Merrem No authorization required for home, outpatient and MD office J2280 Moxifloxacin, 100 mg Avelox No authorization required for home, outpatient and MD office J2770 Quinupristin/dalfopristin, 500 mg (150/350) Synercid No authorization required for home, outpatient and MD office J3095 Injection, telavancin, 10 mg Vibativ No authorization required for home, outpatient and MD office J3243 Tigecycline, 1 mg Tygacil No authorization required for home, outpatient and MD office J0190 Biperiden lactate, per 5 mg Injection Akineton No authorization required for home, outpatient and MD office J0461 Atropine sulfate, 0.01 mg Injection Atropen No authorization required for home, outpatient and MD office J0515 Benztropine mesylate, per 1 mg Injection Cogentin No authorization required for home, outpatient and MD office J3250 Trimethobenzamide HCl, up to 200 mg Tigan No authorization required for home, outpatient and MD office Atropine, inhalation solution, compounded product, administered Atropine No authorization required for home, outpatient and MD office J7635 through DME, concentrated form, per mg Atropine, inhalation solution, compounded product, administered Atropine No authorization required for home, outpatient and MD office J7636 through DME, unit dose form, per mg J1245 Dipyridamole, per 10 mg Persantine No authorization required for home, outpatient and MD office J1642 Heparin sodium, (heparin lock flush), per 10 units Heparin No authorization required for home, outpatient and MD office J1644 Heparin sodium, per 1000 units Heparin No authorization required for home, outpatient and MD office J1645 Dalteparin sodium, per 2500 IU Fragmin No authorization required for home, outpatient and MD office J1650 Enoxaparin sodium, 10 mg Lovenox No authorization required for home, outpatient and MD office J1652 Fondaparinux sodium, 0.5 mg Arixtra No authorization required for home, outpatient and MD office J1655 Tinzaparin sodium, 1000 IU Innohep No authorization required for home, outpatient and MD office J1945 Lepirudin, 50 mg Refludan No authorization required for home, outpatient and MD office J1165 Phenytoin sodium, per 50 mg Phenytoin Sodium No authorization required for home, outpatient and MD office J1953 Levetiracetam, 10 mg Kepra No authorization required for home, outpatient and MD office J0470 Dimercaprol, per 100 mg Bal in Oil No authorization required for home, outpatient and MD office J0600 Edetate calcium disodium, up to 1,000 mg Calcium Disodium Versenate No authorization required for home, outpatient and MD office J0716 Centruroides immune f(ab)2, up to 120 mg Anascorp No authorization required for home, outpatient and MD office J0840 Crotalidae polyvalent immune fab (ovine), up to 1 g Crofab No authorization required for home, outpatient and MD office J1451 Fomepizole, 15 mg Injection Antizol No authorization required for home, outpatient and MD office J2212 Methylnaltrexone, 0.1 mg Relistor Authorization required for all providers J2310 Naloxone HCl, per 1 mg Narcan No authorization required for home, outpatient and MD office J2720 Protamine sulfate, per 10 mg Protamine Sulfate No authorization required for home, outpatient and MD office J2730 Pralidoxime chloride, up to 1 g Protopam No authorization required for home, outpatient and MD office J3520 Edetate disodium, per 150 mg Endrate No authorization required for home, outpatient and MD office Unclassified biologics Raptiva, Vespid, Yellow Hornet Authorization required for all providers, NDC Required Treatment, Yellow Jacket Treatment, Honey Bee Treatment, J3590 Hymenoptera Venom, Venomil, Albay Venomil, Anascorp, Tissuemend J0780 Prochlorperazine, up to 10 mg Compazine No authorization required for home, outpatient and MD office
Load more

Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • Photodynamic Therapy with Methyl Aminolevulinate for Primary Nodular Basal Cell Carcinoma: Results of Two Randomized Studies
    Clinical trial Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies Peter Foley, MBBS, BMedSc, MD, FACD, Michael Freeman, MBBS, FACD, Alan Menter, MB, FAAD, Gregory Siller, MBBS, FACD, Rokea A. El-Azhary, MD, PhD, FAAD, Kurt Gebauer, MBBS, FACD, Nicholas J. Lowe, MD, FAAD, Michael T. Jarratt, MD, FAAD, Dedee F. Murrell, BMBCh, MD, FAAD, Phoebe Rich, MD, FAAD, David M. Pariser, MD, FAAD, Allan R. Oseroff, MD, PhD, FAAD, Ross Barnetson, MD, FRACP, FACD, Christopher Anderson, MBBS, FACD, Steven Kossard, MBBS, FACD, Lawrence E. Gibson, MD, FAAD, and Whitney D. Tope, MPhIL, MD, FAAD From the Department of Medicine Abstract (Dermatology), The University of Background Data suggest that photodynamic therapy using topical methyl aminolevulinate Melbourne, St. Vincent’s Hospital (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell Melbourne, Fitzroy, Vic., Suite 5 ACH carcinoma (BCC). In the studies described here, we investigated the histologic response, House, Benowa and Department of Dermatology, Princess Alexandra tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (£ 5 mm in depth). Hospital, Woolloongabba, Qld, Fremantle Methods Two multicenter, randomized, double-blind studies with similar design and Dermatology, Fremantle, WA, and procedures were conducted. After surface debridement and minor tumor debulking, MAL cream Department of Dermatology, St. George 160 mg/g (66 patients with 75 lesions) or placebo cream (65 patients with 75 lesions) was applied Hospital, University of New South Wales, for 3 h, followed by illumination with broad-spectrum red light (75 J/cm2, 570–670 nm).
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Aminolevulinic Acid (ALA) As a Prodrug in Photodynamic Therapy of Cancer
    Molecules 2011, 16, 4140-4164; doi:10.3390/molecules16054140 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer Małgorzata Wachowska 1, Angelika Muchowicz 1, Małgorzata Firczuk 1, Magdalena Gabrysiak 1, Magdalena Winiarska 1, Małgorzata Wańczyk 1, Kamil Bojarczuk 1 and Jakub Golab 1,2,* 1 Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1A F Building, 02-097 Warsaw, Poland 2 Department III, Institute of Physical Chemistry, Polish Academy of Sciences, 01-224 Warsaw, Poland * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel. +48-22-5992199; Fax: +48-22-5992194. Received: 3 February 2011 / Accepted: 3 May 2011 / Published: 19 May 2011 Abstract: Aminolevulinic acid (ALA) is an endogenous metabolite normally formed in the mitochondria from succinyl-CoA and glycine. Conjugation of eight ALA molecules yields protoporphyrin IX (PpIX) and finally leads to formation of heme. Conversion of PpIX to its downstream substrates requires the activity of a rate-limiting enzyme ferrochelatase. When ALA is administered externally the abundantly produced PpIX cannot be quickly converted to its final product - heme by ferrochelatase and therefore accumulates within cells. Since PpIX is a potent photosensitizer this metabolic pathway can be exploited in photodynamic therapy (PDT). This is an already approved therapeutic strategy making ALA one of the most successful prodrugs used in cancer treatment. Key words: 5-aminolevulinic acid; photodynamic therapy; cancer; laser; singlet oxygen 1. Introduction Photodynamic therapy (PDT) is a minimally invasive therapeutic modality used in the management of various cancerous and pre-malignant diseases.
    [Show full text]
  • Oregon Health Authority Division of Medical Assistance Programs Addendum a - Final OPPS Apcs for CY 2012 Effective October 1, 2012
    Oregon Health Authority Division of Medical Assistance Programs Addendum A - Final OPPS APCs for CY 2012 Effective October 1, 2012 Relative APC Group Title SI Weight 0001 Level I Photochemotherapy S 0.5042 0002 Fine Needle Biopsy/Aspiration T 1.6115 0003 Bone Marrow Biopsy/Aspiration T 3.5702 0004 Level I Needle Biopsy/ Aspiration Except Bone Marrow T 4.5746 0005 Level II Needle Biopsy/Aspiration Except Bone Marrow T 8.1566 0006 Level I Incision & Drainage T 1.4206 0007 Level II Incision & Drainage T 13.1250 0008 Level III Incision and Drainage T 20.5648 0012 Level I Debridement & Destruction T 0.3878 0013 Level II Debridement & Destruction T 0.8785 0015 Level III Debridement & Destruction T 1.4989 0016 Level IV Debridement & Destruction T 2.7592 0017 Level V Debridement & Destruction T 21.6661 0019 Level I Excision/ Biopsy T 4.4238 0020 Level II Excision/ Biopsy T 8.2746 0021 Level III Excision/ Biopsy T 17.0074 0022 Level IV Excision/ Biopsy T 23.2662 0028 Level I Breast Surgery T 25.5054 0029 Level II Breast Surgery T 33.4070 0030 Level III Breast Surgery T 44.8999 0031 Smoking Cessation Services X 0.2997 0034 Mental Health Services Composite S 2.7295 0035 Vascular Puncture and Minor Diagnostic Procedures X 0.2691 0037 Level IV Needle Biopsy/Aspiration Except Bone Marrow T 15.3499 0039 Level I Implantation of Neurostimulator Generator S 216.7598 0040 Level I Implantation/Revision/Replacement of Neurostimulator Electrodes S 63.7616 0041 Level I Arthroscopy T 29.6568 0042 Level II Arthroscopy T 57.0137 0045 Bone/Joint Manipulation Under
    [Show full text]
  • Pub 100-04 Medicare Claims Processing
    Department of Health CMS Manual System & Human Services (DHHS) Pub 100-04 Medicare Claims Centers for Medicare Processing & Medicaid Services (CMS) Transmittal 2128 Date: DECEMBER 29, 2010 Change Request 7275 SUBJECT: January 2011 Update of the Ambulatory Surgical Center (ASC) Payment System I. SUMMARY OF CHANGES: This Recurring Update Notification describes changes to and billing instructions for various payment policies implemented in the January 2011 ASC update. As appropriate, this notification also includes updates to the Healthcare Common Procedure Coding System (HCPCS). EFFECTIVE DATE: January 1, 2011 IMPLEMENTATION DATE: January 3, 2011 Disclaimer for manual changes only: The revision date and transmittal number apply only to red italicized material. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents. II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual is not updated) R=REVISED, N=NEW, D=DELETED-Only One Per Row. R/N/D CHAPTER / SECTION / SUBSECTION / TITLE N/A III. FUNDING: For Fiscal Intermediaries (FIs), Regional Home Health Intermediaries (RHHIs): No additional funding will be provided by CMS; Contractor activities are to be carried out within their operating budgets. For Medicare Administrative Contractors (MACs): The Medicare Administrative Contractor is hereby advised that this constitutes technical direction as defined in your contract. CMS does not construe this as a change to the MAC Statement of Work. The contractor is not obligated to incur costs in excess of the amounts allotted in your contract unless and until specifically authorized by the Contracting Officer.
    [Show full text]
  • APPENDICES: a Systematic Review of Photodynamic Therapy in the Treatment of Pre-Cancerous Skin Conditions, Barrett's Oesophagu
    Health Technology Assessment 2010; Vol. 14: No.371 Health Technology Assessment 2010; Vol. 14: No. 37 Appendix 5 Pre-cancerous skin scoping Appendix 6 Appendices Go to main text Skin cancer scoping Appendix 7 Barrett’s oesophagus scoping Appendix 8 Oesophageal cancer scoping A systematic review of photodynamic Appendix 9 therapy in the treatment of pre- Lung cancer scoping cancerous skin conditions, Barrett’s Appendix 10 oesophagus and cancers of the biliary Biliary tract cancer scoping Appendix 11 tract, brain, head and neck, lung, Brain cancer scoping oesophagus and skin Appendix 12 Head and neck cancer scoping D Fayter, M Corbett, M Heirs, D Fox Appendix 13 and A Eastwood Actinic keratosis data extraction Appendix 14 Bowen’s disease data extraction Appendix 15 Basal cell carcinoma data extraction Appendix 16 Barrett’s oesophagus data extraction Appendix 17 Oesophageal cancer data extraction Appendix 18 Lung cancer data extraction Appendix 19 Biliary tract cancer data extraction Appendix 20 Brain cancer data extraction Appendix 21 July 2010 Head and neck cancer data extraction 10.3310/hta14370 Health Technology Assessment NIHR HTA programme www.hta.ac.uk HTA How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below). Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.
    [Show full text]
  • Impact of Intramammary Treatment on Gene Expression Profiles in Bovine Escherichia Coli Mastitis
    Impact of Intramammary Treatment on Gene Expression Profiles in Bovine Escherichia coli Mastitis Anja Sipka1*, Suzanne Klaessig1, Gerald E. Duhamel2, Jantijn Swinkels3, Pascal Rainard4,5, Ynte Schukken1 1 Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, United States of America, 2 Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, United States of America, 3 GD Animal Health Center, Deventer, The Netherlands, 4 INRA, UMR1282, Infectiologie Animale et Sante´ Publique, Nouzilly, France, 5 Universite´ Franc¸ois Rabelais de Tours, UMR1282 ISP, Tours, France Abstract Clinical mastitis caused by E. coli accounts for significant production losses and animal welfare concerns on dairy farms worldwide. The benefits of therapeutic intervention in mild to moderate cases are incompletely understood. We investigated the effect of intramammary treatment with cefapirin alone or in combination with prednisolone on gene expression profiles in experimentally-induced E. coli mastitis in six mid-lactating Holstein Friesian cows. Cows were challenged with E. coli in 3 quarters and received 4 doses of 300 mg cefapirin in one quarter and 4 doses of 300 mg cefapirin together with 20 mg prednisolone in another quarter. At 24 h (n = 3) or 48 h (n = 3) post-challenge, tissue samples from control and treated quarters were collected for microarray analysis. Gene expression analysis of challenged, un-treated quarters revealed an up-regulation of transcripts associated with immune response functions compared to un-challenged quarters. Both treatments resulted in down-regulation of these transcripts compared to challenged, un-treated quarters most prominently for genes representing Chemokine and TLR-signaling pathways.
    [Show full text]